Visepegenatide
Sources
registry, as of 2025-11-19Stale
https://clinicaltrials.gov/study/NCT06350812
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor PegBio Co., Ltd.. Enrollment 32. Conditions Obesity. The trial is conducted in a single-center, randomized, double-blind, placebocontrolled, dose-increasing design. To evaluate the safety, tolerability, pharmacokinetics(PK) characteristics, efficacy and immunogenicity of PB-119 injection in Chinese obese subjects.
ClinicalTrials.gov NCT06350812 protocol and results modules